December 16, 2015

Pioneering Studies Apply New Immunologic Insights to Glioblastoma

Clinical trial to launch in 2016

650×450-MDSC

Cleveland Clinic neurosurgeons and cancer biologists are hopeful that recent discoveries they have made about the role myeloid-derived suppressor cells (MDSCs) play in glioblastoma will open a pathway to novel treatments for this uniformly fatal brain tumor. Planning for a clinical trial is underway.

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

“This effort is particularly timely because of the current enormous focus on understanding the immune system’s function in the context of cancer,” says Michael A. Vogelbaum, MD, PhD, Associate Director of Cleveland Clinic’s Rose Ella Burkhardt Brain Tumor and NeuroOncology Center. “Currently, the only effective treatments for cancers that arise in the brain itself include surgery, radiation therapy and a very small number of conventional chemotherapies.

“Immunotherapies are showing clinical promise in a variety of cancers,” continues Dr. Vogelbaum, who is also Professor of Neurosurgery at Cleveland Clinic Lerner College of Medicine. “The proving ground has been melanoma, but there are numerous immunotherapy clinical trials now underway for brain tumors as well. While the failure of most chemotherapies can be attributed largely to the fact that they do not get into the brain at effective concentrations, immunotherapies may not be as impacted by that limitation.”

MDSCs in glioblastoma

Dr. Vogelbaum’s work with MDSCs dates back to research he conducted with James H. Finke, PhD, a scientist in Cleveland Clinic’s Lerner Research institute who helped elucidate the biological role MDSCs play in renal cell carcinoma. Now Dr. Vogelbaum is teaming with another Lerner Research Institute scientist, Justin D. Lathia, PhD, and his colleagues in the Department of Cellular and Molecular Medicine to explore the critical role MDSCs play in glioblastoma.

MDSCs are a heterogeneous class of immature immunosuppressive cells found in various tumors and at the sites of inflammation, infection and injury. In the latter, MDSCs modulate the immune response. In cancer, they suppress beneficial cytotoxic immune cell function, in turn contributing to tumor growth and metastasis. Drs. Finke and Vogelbaum’s groups discovered that, as in patients with renal cell carcinoma, MDSCs are upregulated in the peripheral blood of glioblastoma patients. Dr. Lathia’s lab has built on that work most recently by showing that MDSCs find their way into the brain where they communicate with self-renewing cancer stem cells (CSCs) present in many advanced tumors.

“In our preclinical studies with a mouse model of glioblastoma, our key finding was that MDSCs communicate directly with CSCs to modulate their behavior,” Dr. Lathia says. “It is not that the MDSCs migrate into the tumor microenvironment and suppress immunity. Rather, they interact with CSCs, secreting molecules that activate MDSCs. This alters the immune system and promotes tumor growth — and it appears to be an important mechanism in glioblastoma immune evasion.”

Advertisement
Job # 104733 Valleriano 10-29-15

Drs. Lathia (left) and Vogelbaum together in the lab.

Translating to therapeutics

Drs. Vogelbaum and Lathia have collaborated to develop a novel chemotherapeutic strategy aimed at reducing MDSC levels in the bloodstream to reverse immunosuppression and activate the patient’s immune system against tumor progression. They are working with Cleveland Clinic medical oncologist David Peereboom, MD, who specializes in the treatment of patients with brain tumors and will serve as primary investigator of the clinical trial based on this new strategy.

Targeting MDSCs actually reverses the suppressive effects the immune system displays, allowing it to function more normally and recognize tumor cells and stop their growth, Dr. Lathia explains.

What distinguishes this approach

“The rationale behind many immunotherapy efforts is to accelerate the immune system by disrupting immune suppressive mechanisms within the tumor,” Dr. Lathia says. “What we are proposing instead is to use current inhibitors that activate the immune system and at the same time directly eliminate MDSCs from the bloodstream and bone marrow, not within the tumor. We want to prevent MDSCs from reaching the brain in the first place.”

Another exciting aspect of the proposed therapeutic approach is that it does not depend on the MDSC-killing agent crossing the blood-brain barrier, Dr. Vogelbaum notes. Instead, MDSCs will be targeted in the peripheral blood of glioblastoma patients using FDA-approved chemotherapeutic agents, starting with 5-fluorouracil, which has demonstrated effectiveness in killing MDSCs in mouse studies. The team has ongoing efforts looking at other perhaps more effective agents as well.

Advertisement

Improved understanding portends better-targeted treatment

“Our understanding of how the immune system operates in the brain in normal as well as in pathological conditions is improving,” Dr. Lathia comments. “This knowledge should help us target these infiltrating cell populations as alternative therapies to encourage patients’ own immune systems to successfully attack glioblastoma tumors.”

“We believe that some form of immunotherapy or immunostimulation alone or in combination with conventional treatments has the potential to help people with malignant brain tumors live longer,” concludes Dr. Vogelbaum.

The team hopes to begin enrolling patients in the clinical trial within the next six months.

Related Articles

Cleveland Clinic physiatrist
March 22, 2024
The Vital Role of Oncology Rehabilitation (Podcast)

New program provides prehabilitation and rehabilitation services to help patients with cancer maintain and regain function

Doctors working on MGUS screening study
March 18, 2024
Pilot Study Aims for Early Identification of Multiple Myeloma Precursor Among Black Patients

First-of-its-kind research investigates the viability of standard screening to reduce the burden of late-stage cancer diagnoses

Hematologist at Cleveland Clinic
March 14, 2024
Advances in Mantle Cell Lymphoma Treatment (Podcast)

Global R&D efforts expanding first-line and relapse therapy options for patients

Physician with patient
March 6, 2024
Targeting Uncontrolled Erythrocytosis in Polycythemia Vera with Rusfertide

Study demonstrates ability to reduce patients’ reliance on phlebotomies to stabilize hematocrit levels

Dr. Jagadeesh at Cleveland Clinic
February 28, 2024
Treating Patient with Systemic T-Cell Lymphoma and Graft-Versus-Host Disease

A case study on the value of access to novel therapies through clinical trials

Doctor measuring patient's waist size
February 26, 2024
Impact of Obesity on GVHD & Transplant Outcomes in Hematologic Malignancies

Findings highlight an association between obesity and an increased incidence of moderate-severe disease

Physician with patient
February 21, 2024
Strategies for Improving Clinical Trial Equity

Cleveland Clinic Cancer Institute takes multi-faceted approach to increasing clinical trial access

How antibody drug conjugates work
February 13, 2024
Real-World Use of Trastuzumab Deruxtecan

Key learnings from DESTINY trials

Ad